Many other correlates of immune activation and/or cular significance in this regard are immune mechanisms, which, in response to certain signals, could inflammatory activity have also been shown to be either uniquely present or significantly elevated in the invoke inflammatory cascades in the brain that exacerbate the degenerative process and result in chronic brains of AD patients, when compared to age-matched, non-demented controls. Included among these are neurologic disease.
There is now substantial evidence of inflammatory several 'acute phase response' proteins, such as ␣ 1 -antichymotrypsin, 10 ␣ 2 -macroglobulin, 11 C-reactive activity in AD, [1] [2] [3] [4] though the molecular signals that trigger this immune action have yet to be resolved.
protein, 12 amyloid P 13 and sulfated proteoglycans. 14 The acute phase response is the terminology given to Also unclear, is how the response of parenchymal brain cells to these signals is linked to the neurodegenthe rapid adjustment of plasma protein composition in response to injurious stimuli, 15 and the presence in the eration and cognitive decline typical of AD presentation. Accordingly, this review focuses on the followbrain of proteins characteristic of this condition underscores inflammatory activity in AD. ing two issues: 1) the putative role for A␤ as a stimulus for immune activation and neuroinflammation; and 2) Other significant markers of inflammatory involvement in AD include several proteins of the complement the contribution of microglia and astrocytes to the inflammatory response, and in mediating neuronal system, 16 the function of which includes cytolysis, opsonization of particles for phagocytosis, production degeneration in AD.
of inflammatory mediators and clearance of immune complexes. 15 Specifically, all proteins of the classical complement pathway, [17] [18] [19] uniquely associated with AD lesions or significantly elevated in AD brain in comparison to age-matched cells in synaptic reorganization during the natural course of development, as well as in ischemia-induced controls. In possible relation to the destructive actions of the complement system, the detection in senile neuronal injury (reviewed in Ref 26) . It is further acknowledged that tissue macrophages may be actiplaques of heightened levels of elements of the clotting cascades, notably the serine protease thrombin, 21 antivated to a cytotoxic state by a variety of xenobiotics, and induced to release a diverse array of destructive thrombin III, 22 and Hageman factor (the plasma protein that initiates clotting), 23 additionally suggests tissue compounds including reactive oxygen and nitrogen intermediates, hydrolytic enzymes, lipids and cytoremodeling associated with inflammation in AD lesions.
kines. 37 By analogy, similar destructive behavior might be elicited in brain macrophages in response to proPerhaps the evidence most indicative of inflammatory involvement in AD brain is enhanced expression teins uniquely, or overly, expressed in the brains of AD patients. In fact, several studies strongly suggest the of the cytokine network. 24 Cytokines are a heterogeneous group of proteins that regulate varied immune possibility that A␤ peptide could function in situ as a facultative 'inflammagen', able to provoke the release and inflammatory responses, both in the periphery and CNS, and which may be produced by either circulating of neurotoxins and pro-inflammatory agents from surrounding microglia. Exposure of cultured peritoneal leukocytes or parenchymal tissue cells. Of parenchymal brain cells, the major cytokine-producers are astromacrophages to synthetic A␤ has been shown to result in homotypic aggregation of these cells, increased rescytes and microglia, 25 the latter generally considered to be of monocyte/macrophage lineage and the brain's piratory burst activity, and elevated production of the highly neurodestructive compound nitric oxide (NO).
38 resident mononuclear phagocyte. 26 The specific cytokines interleukin-1 (IL-1), IL-3, IL-6 and tumor necrosis
In synergism with interferon-␥, A␤ can also trigger production of TNF-␣ and another toxic nitrogen interfactor-␣ (TNF-␣) have been reported to be elevated in brain tissue homogenates from patients with AD, [27] [28] [29] mediate, NO − 2 39 from microglial cells. A␤ has further been demonstrated to be chemotactic for microglia, 40 and heightened IL-1 immunoreactivity has been detected in CSF of AD-afflicted individuals. 30 Histoand to stimulate microglial production of IL-1. 41 As IL-1 can potentiate the cytotoxicity of A␤ in neuronal logically, IL-1 has further been observed in astrocytes and microglia in situ, in intimate association with sencell culture, 42 as well as promote NO release from astrocytes, 43 and TNF-␣ can promote the release of ile plaques. 31 reactive nitrogen intermediates from microglia, 39 there is clearly a potential link between A␤ deposition, Is A␤ a signal for immune activation and microglial activation and neuronal cell death.
inflammation?
Direct evidence that A␤-induced activation of monocytes/macrophages can actually result in neural Despite the clear signs of inflammatory activity present in AD brain, several questions remain regarding their injury has recently been demonstrated in this laboratory. 44 Specifically, it was observed that exposure of significance to AD pathogenesis and disease progression. For example, what is the nature and origin of human peripheral blood monocytes to aggregated, synthetic A␤ peptide induced cell clumping typical of the the inflammatory process? Do these inflammatory indicators simply reflect epiphenomena associated with activated state, as well as cytopathic activity upon subsequent incubation of these cells with neural tissue. A neural repair mechanisms, or are they fundamental to the pathogenic process? And, how is inflammation similar neurotoxic response has been shown by human microglial cells incubated with senile plaques purified related to the chronic, degenerative condition characteristic of AD? Possible clues to these queries may lie from AD brain, 45 as well as by murine microglia stimulated with either synthetic A␤ peptide or its fragment in neuropathologic observations. In this regard, A␤-containing, senile plaques of the neuritic (containing A␤ (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) (35) . 39 Collectively, these findings underscore the prospect that aggregated A␤ peptide is a sufficient dystrophic neurites) and core types are typically surrounded by immunoreactive microglia and astrocytes, stimulus for immune activation within the brain. Precisely how the presence of insoluble A␤ is transas well as by various pro-inflammatory cytokines and other acute phase proteins (for reviews on this topic duced into an inflammatory response is presently a matter of conjecture, though phagocytic activity of the see Refs 24, 32, 33) . Given that both these cell types harbor the potential for releasing a variety of neurosurrounding cells may play an important role. Employing immunocytochemistry to detect A␤ in necrotic toxic and vasoactive substances (reviewed in Refs 34, 35) , and can communicate with each other via a comhuman brain tissue, Wisniewski et al noted that perivascular macrophages (microglial-related cells contained plicated cytokine network, 25 an attractive hypothesis is that aggregated A␤ peptide triggers an inflammatory within the basement membrane of blood vessels) appeared to be involved in the phagocytosis and digesresponse within the adjacent glial population. This response, in turn, could set into motion a cascade of tion of amyloid fibrils of neuritic plaques. 46 Similarly, Frautschy et al 47 observed amyloid immunoreactivity glial-mediated neurocytopathic events leading to destruction of neural tissue. 36 within phagocytes of rat brain after intracerebral injection of amyloid-containing plaque core material. In That microglia can respond to local environmental factors in a neurodestructive manner is well estabcontrast, cultured microglia have been shown to exhibit only limited effectiveness in degrading purified lished, and highlights the recognized role for these amyloid cores in vitro, 48 though being able to rapidly inflammatory drug that inhibits prostaglandin synthesis and can retard leukocyte motility, 56 has been internalize purified A␤. 49 As the phagocytic process can trigger secretion of cytotoxic substances, 37 the shown to significantly lessen the diminution in cognitive performance exhibited by AD patients over a 6-response to deposits of A␤ in vivo may be dependent upon A␤ uptake, degradation and processing by perimonth period, when contrasted with placebo treatment of other AD-afflicted individuals. vascular macrophages, or, alternatively, initiated by 'frustrated phagocytosis' of the aggregated peptide by As regards experimental data, pretreatment of cultured neuronal cells with either indomethacin, or one parenchymal microglia that are deeply invested within the senile plaques.
of two other anti-inflammatory compounds, the steroid dexamethasone or the anti-malarial agent chloroquine, While accumulating evidence clearly points to there being acute microglial reponsiveness to A␤, reactions has been reported to lessen the toxicity of A␤. 42 Recent observations made in our laboratory further indicate of astrocytes may additionally contribute to neuronal cell death in AD. 50 In this regard, human astrocytes that indomethacin and dexamethasone are also effective in inhibiting the neurotoxic response of A␤-have been reported to release significantly greater amounts of NO in response to cytokine stimulation stimulated monocytes (unpublished data). Similarly, chloroquine has been shown to be effective in reducing than do microglial cells. 43 Given the known communicative pathways between astrocytes and microglia, 25 it ischemic injury of rat CNS tissue in vivo, coincident with its ability to inhibit phagocytic activity in is plausible that pathological consequences of microglial activation in vivo may also stem from secondary monocytes/macrophages/microglia. 57 Further antagonism of neurotoxic effects of activated microglia has stimulation of astrocytes by microglial-derived mediators. Such inter-dependent mechanisms of A␤-been demonstrated for the immunosuppressive cytokine interleukin-4, 58 and additionally highlights the induced neurotoxicity could significantly intensify the pathogenic process.
prospect of clinical interdiction of mononuclear phagocyte function in attempting to mitigate neurodegenerFinally, reactive glia can also potentially effect vascular disturbances that may impact on the progression ative disease. Whatever the specific etiologic agent in AD, if indeed of AD. Inasmuch as both astrocytes and microglia form intimate contacts with the endothelial cells comprising there is any one factor, it is fair to conclude that reactive inflammatory mechanisms within the brain the BBB, 51 A␤-induced glial release of vasoactive cytokines and toxins could significantly alter microvascular can only serve to exacerbate the initial insult and worsen the condition. Thus, even therapeutic interpermeability, upregulate the expression of endothelial/ leukocyte adhesion molecules and promote leukocyte vention directed downstream from the incipient event in AD heralds the prospect of patient benefit. With extravasation. In turn, release of cytokines by such activated endothelial cells or invading leukocytes could increasing awareness of the vastly destructive effects of CNS inflammation, and, in particular, the preemiexacerbate the glial reponse to A␤. Thus, there exists the potential for A␤ to ignite a succession of self-propanent role played by glial cells in this process, efforts aimed at lessening the responsiveness of these cells to gating inflammatory reactions culminating in progressive neurodegeneration. That inflammatory processes A␤ merit serious consideration as potential palliative therapy for AD. can also induce alterations in beta-amyloid precursor protein, 52 from which A␤ is derived, provides yet additional fuel to drive vicious cycles of A␤ accumuAcknowledgements lation, neuroinflammation and neuronal cell death.
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